Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Atherosclerosis, Acute Coronary Syndrome (ACS)

In brief

The primary objective of this study is to demonstrate that the efficacy of cangrelor (combined with usual care) is superior to that of usual care, in subjects requiring percutaneous coronary intervention (PCI) as measured by a composite of all-cause mortality, myocardial infarction (MI), and ischemia-driven revascularization (IDR).

Key facts

Study ID

NCT00385138

Run by

The Medicines Company

People needed

5364

Starts

2006-09-01

Expected to finish

2010-06-01

Last updated by the study team

2014-05-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Angiography demonstrating atherosclerosis amenable to treatment by percutaneous coronary intervention (PCI) with or without stent implantation and diagnosis of Acute Coronary Syndrome (ACS) by elevated cardiac markers or ischemic chest discomfort w/electrocardiogram changes + age > 65 or diabetes.

You may not qualify if…

• Not a candidate for PCI
• ST-segment elevation myocardial infarction (STEMI) within 48 hours of randomization
• Increased bleeding risk: ischemic stroke within the last year or any previous hemorrhagic stroke, intra-cranial tumor, cerebral arteriovenous malformation, or intracranial aneurysm; recent (<1 month) trauma or major surgery [including coronary artery bypass graft (CABG) surgery]; currently receiving warfarin, active bleeding
• Impaired hemostasis: known International Normalized Ratio (INR) >1.5 at screening; past or present bleeding disorder (including congenital bleeding disorders such as von Willebrand's disease or hemophilia, acquired bleeding disorders, and unexplained clinically significant bleeding disorders), thrombocytopenia (platelet count <100,000/µL) at screening
• Severe hypertension not adequately controlled by antihypertensive therapy at the time of randomization
• Receipt of fibrinolytic therapy in the 12 hours preceding randomization
• Receipt of any thienopyridine (clopidogrel or ticlopidine) in the 7 days preceding randomization
• Glycoprotein IIb/IIIa (GPI) Inhibitor usage within the previous 12 hours [applicable to unstable angina (UA) and non-ST-elevation myocardial infarction (NSTEMI) patients]

Where it is running

• Innovis Health — Fargo, North Dakota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.